Fu Zhuo, Wang Ming-Wei, Liu Ya-Hui, Jiao Yan
Medical College, Inner Mongolia Minzu University, Tongliao 028000, Inner Mongolia Autonomous Region, China.
Ministry of Health Key Laboratory of Radiobiology, School of Public Health of Jilin University, Changchun 130000, Jilin Province, China.
World J Gastrointest Surg. 2024 Jul 27;16(7):1969-1972. doi: 10.4240/wjgs.v16.i7.1969.
This editorial discusses the article "Analysis of the impact of immunotherapy efficacy and safety in patients with gastric cancer and liver metastasis" published in the latest edition of the . Immunotherapy has achieved outstanding success in tumor treatment. However, the presence of liver metastasis (LM) restrains the efficacy of immunotherapy in various tumors, including lung cancer, colorectal cancer, renal cell carcinoma, melanoma, and gastric cancer. A decrease in CD8+ T cells and nature killer cells, along with an increase in macrophages and regulatory T cells, was observed in the microenvironment of LM, leading to immunotherapy resistance. More studies are necessary to determine the best strategy for enhancing the effectiveness of immunotherapy in patients with LM.
这篇社论讨论了发表在最新一期《 》上的文章《胃癌肝转移患者免疫治疗疗效和安全性的影响分析》。免疫疗法在肿瘤治疗中取得了显著成功。然而，肝转移（LM）的存在限制了免疫疗法在包括肺癌、结直肠癌、肾细胞癌、黑色素瘤和胃癌在内的各种肿瘤中的疗效。在LM的微环境中观察到CD8 + T细胞和自然杀伤细胞减少，同时巨噬细胞和调节性T细胞增加，导致免疫治疗耐药。需要更多的研究来确定提高LM患者免疫治疗效果的最佳策略。
